RTP Mobile Logo

Friday, December 8, 2017, Atlanta, Georgia, 6:00 PM – 9:00 PM (Eastern Time)

Addressing Current Questions and Controversies in the Management of Multiple Myeloma, Waldenström Macroglobulinemia and Amyloidosis (Part 2 of a 2-Part Series)

A Friday Satellite Symposia Series Preceding the 59th ASH Annual Meeting

Event Details

Location:
Atlanta Marriott Marquis
265 Peachtree Center Avenue
Atlanta, GA 30303
Hotel Phone: 404-521-0000

Event Times:
6:00 PM – 6:30 PM (Eastern Time) — Registration and Dinner Buffet
6:30 PM – 9:00 PM (Eastern Time) — Educational Meeting

Meeting Room:
Marquis Ballroom B-D (Marquis Level)

There is no registration fee for this event. However, preregistration is advised, as seating is limited.

Faculty:
Meletios A Dimopoulos, MD
Chairman, Department of Medical Therapeutics
University of Athens School of Medicine
Athens, Greece

Sagar Lonial, MD
Professor and Executive Vice Chair
Department of Hematology and Medical Oncology
Chief Medical Officer
Winship Cancer Institute
Emory University
Atlanta, Georgia

Nikhil C Munshi, MD
Professor of Medicine, Harvard Medical School
Director of Basic and Correlative Science
Associate Director, Jerome Lipper
Multiple Myeloma Center
Department of Medical Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts

Robert Z Orlowski, MD, PhD
Florence Maude Thomas
Cancer Research Professor
Chair ad interim
Department of Lymphoma and Myeloma
Professor, Department of
Experimental Therapeutics
Division of Cancer Medicine
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Noopur Raje, MD
Director, Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Moderator:
Neil Love, MD
Research To Practice
Miami, Florida



Agenda

This activity, the second in a 2-part series, will focus on common practical issues and challenges encountered by clinicians caring for patients with multiple myeloma (MM) and related disorders. Prior to the event, Research To Practice will consult with 5 community-based medical and hematologic oncologists to identify specific clinical situations or questions for which they would seek investigator input. The meeting will feature a faculty panel of 5 renowned investigators and will be divided into 5 modules, each focused on a distinct subset of MM, including Waldenström macroglobulinemia and amyloidosis. Each module will include a discussion of the questions and issues presented by the consulting oncologists and a faculty member-led review of relevant ongoing research. Clinicians in attendance will use networked iPads® to participate in a premeeting survey related to the topics and questions to be discussed. Polling results will be interspersed throughout each discussion to elucidate any knowledge and practice gaps that may exist within the community. A full agenda will be made available in the fall.

CE Information

Target Audience:
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of multiple myeloma (MM), Waldenström macroglobulinemia (WM) and amyloidosis (AL).

Learning Objectives:
At the conclusion of this activity, participants should be able to:

  • Customize the use of induction, consolidation and maintenance therapeutic approaches for patients with MM in the post-transplant and nontransplant settings, considering patient- and disease-related factors, including cytogenetic profile.
  • Consider published research data and other clinical factors in the best-practice selection, sequencing or combining of available therapies in the nonresearch care of patients with relapsed/refractory (R/R) MM.
  • Appreciate the mechanisms of action of, supportive research database with and FDA-endorsed indications for monoclonal antibodies directed at CD-38 and SLAM-F7, and effectively identify where and how these agents should be integrated into the clinical management of R/R MM.
  • Design and implement a plan of care to recognize and manage side effects and toxicities associated with the use of existing and recently approved systemic therapies to support quality of life and continuation of treatment.
  • Develop an evidence-based algorithm for the use of stem-cell transplant, chemotherapy and/or novel targeted agents for the management of primary AL.
  • Consider clinical and other patient-related factors in the sequence and selection of systemic therapy for patients with WM requiring active treatment.
  • Assess the ongoing clinical trials evaluating novel investigational approaches for MM, WM and AL, and obtain consent from appropriate patients for study participation.

CME Credit Form:
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement:
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement:
Research To Practice designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy:
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

Supporters:
This activity is supported by educational grants from AbbVie Inc, Adaptive Biotechnologies, AstraZeneca Pharmaceuticals LP/Acerta Pharma, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Genentech BioOncology, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Pharmacyclics LLC, an AbbVie Company, Seattle Genetics and Takeda Oncology.

Location

Atlanta Marriott Marquis
265 Peachtree Center Avenue
Atlanta, GA 30303
Hotel Phone: 404-521-0000

Meeting Room:
Marquis Ballroom B-D (Marquis Level)

Directions:
The Atlanta Marriott Marquis Hotel is conveniently located within 1 mile of the Georgia World Congress Center where the ASH Annual Meeting is taking place.

 

Registration

This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of multiple myeloma (MM), Waldenström macroglobulinemia (WM) and amyloidosis (AL).

There is no registration fee for this event. However, preregistration is advised, as seating is limited.

Registration for clinicians in practice

I am a practicing physician, fellow or other healthcare provider involved in the treatment of cancer.

Registration for clinicians in practice »
 
Registration for other/industry professionals*

Please note, a limited number of seats are currently available for nonclinicians on a first come, first served basis.

Registration for other/ industry professionals »

* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating, please check in at our onsite registration desk at least one half hour prior to the start of the meeting. We cannot guarantee seating after the start of the program.

Meal service will be provided to those who attend the program, based on availability.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future CME programs.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.